Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Market Movers
TipRanks 50 Index
AI Stocks
Largest Companies by Market Cap
ETFs
Top ETFs by Upside
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Ideas
Plans
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Trump Dashboard
New
Most Shorted Stocks
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Economic Indicators
Inflation Rate
Unemployment Rate
Class Actions
Tools
Plans
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Screeners
Plans
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Dividends
Plans
My Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Experts
Plans
Portfolio
Plans
Trending News
More News >
News
Plans
Investors
Private Companies
Plans
Enterprise Solutions
Plans
Education
Personal Finance
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Careers
Contact Us
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
MCP for Agents
Advertise with Us
Top Online Brokers
Gold IRA Companies
Become an Affiliate
TipRanks News Wire
Follow Us
More
Plans
Plans
Plans
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Screeners
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Ideas
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Research Tools
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Most Shorted Stocks
Calculators
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividends
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Market Movers
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Center
Investors
Personal Finance
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
More
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Gold IRA Review
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Log Out
Advertisement
Advertisement
DMRA
Stock Latest News
Ratings
Damora Maintained at Buy as Analyst Cites Strong mutCALR Pipeline, Robust Cash Runway and Reaffirms $45 Price Target
10d ago
DMRA
Premium
Ratings
Analyst Reiterates Buy on Damora Therapeutics, Maintains $45 Price Target on Differentiated Clinical Strategy
10d ago
DMRA
Premium
Ratings
Analyst Initiates Buy on Damora Therapeutics Citing Strong mCALR Pipeline, Accelerated CLARITY-101 Readouts, and Funding Runway Into 2029
10d ago
DMRA
Premium
Ratings
Sam Slutsky Reiterates Buy Rating on Damora Therapeutics, Maintains $45 Price Target on Promising DMR-001 Profile
15d ago
DMRA
Premium
The Fly
Damora Therapeutics price target raised to $40 from $35 at Wedbush
22d ago
DMRA
INCY
Premium
The Fly
Damora Therapeutics initiated with a Buy at Jefferies
25d ago
DMRA
INCY
Premium
Ratings
Damora Therapeutics: Buy Rating Reaffirmed on Differentiated ET/MF Candidate and $50 Price Target
25d ago
DMRA
Premium
Company Announcements
Damora Therapeutics Completes Cayman Islands Redomestication
1M ago
8K
DMRA
Premium
The Fly
Damora Therapeutics completes redomestication to the Cayman Islands
1M ago
DMRA
Premium
Company Announcements
Damora Therapeutics Announces Results of 2026 Annual Meeting
2M ago
8K
DMRA
Premium
The Fly
Damora Therapeutics initiated with a Buy at H.C. Wainwright
2M ago
DMRA
Premium
The Fly
Wedbush bullish on Damora Therapeutics, initiates with an Outperform
3M ago
DMRA
INCY
Premium
The Fly
Damora Therapeutics initiated with an Outperform at Wedbush
3M ago
DMRA
Premium
Company Announcements
Damora Therapeutics Announces CFO Transition to Internal Leader
4M ago
8K
DMRA
Premium
The Fly
Damora Therapeutics initiated with an Outperform at RBC Capital
4M ago
DMRA
Premium
The Fly
Damora Therapeutics initiated with an Outperform at Evercore ISI
5M ago
DMRA
Premium
Company Announcements
Damora Therapeutics Announces Major Leadership and Board Overhaul
5M ago
8K
DMRA
Premium
The Fly
Damora names Peter Harwin chairman, appoints Spyre Therapeutics CEO to board
5M ago
DMRA
SYRE
Premium
The Fly
Damora Therapeutics appoints Jennifer Jarrett as CEO
5M ago
DMRA
RCUS
Premium
Ratings
Damora Therapeutics: Buy Rating on Differentiated CALR Pipeline, Clear Regulatory Path, and Solid Cash Runway
5M ago
DMRA
Trending
Indices
Stocks
ETFs
Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >
You need to enable JavaScript to run this app.
